(NASDAQ: ALDX) Aldeyra Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.23%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.39%.
Aldeyra Therapeutics's revenue in 2026 is $0.On average, 8 Wall Street analysts forecast ALDX's revenue for 2026 to be $1,664,595,567, with the lowest ALDX revenue forecast at $0, and the highest ALDX revenue forecast at $5,175,418,338. On average, 7 Wall Street analysts forecast ALDX's revenue for 2027 to be $1,009,686,534, with the lowest ALDX revenue forecast at $0, and the highest ALDX revenue forecast at $2,296,635,144.
In 2028, ALDX is forecast to generate $4,551,683,985 in revenue, with the lowest revenue forecast at $4,373,181,854 and the highest revenue forecast at $4,685,530,493.